F98 Stock Overview
A pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
CytoMed Therapeutics Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.79 |
52 Week High | US$3.82 |
52 Week Low | US$1.71 |
Beta | 0 |
11 Month Change | 0.56% |
3 Month Change | -10.50% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -50.69% |
Recent News & Updates
Recent updates
Shareholder Returns
F98 | DE Biotechs | DE Market | |
---|---|---|---|
7D | -1.6% | -3.0% | -0.1% |
1Y | n/a | -19.4% | 2.3% |
Return vs Industry: Insufficient data to determine how F98 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how F98 performed against the German Market.
Price Volatility
F98 volatility | |
---|---|
F98 Average Weekly Movement | 7.9% |
Biotechs Industry Average Movement | 6.5% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: F98 has not had significant price volatility in the past 3 months.
Volatility Over Time: F98's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | n/a | Wee Kiat Tan | w2.cytomed.sg |
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.
CytoMed Therapeutics Limited Fundamentals Summary
F98 fundamental statistics | |
---|---|
Market cap | €22.33m |
Earnings (TTM) | -€2.84m |
Revenue (TTM) | €348.48k |
64.1x
P/S Ratio-7.9x
P/E RatioIs F98 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
F98 income statement (TTM) | |
---|---|
Revenue | S$507.74k |
Cost of Revenue | S$3.73k |
Gross Profit | S$504.01k |
Other Expenses | S$4.64m |
Earnings | -S$4.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.36 |
Gross Margin | 99.27% |
Net Profit Margin | -813.99% |
Debt/Equity Ratio | 3.9% |
How did F98 perform over the long term?
See historical performance and comparison